Skip to main content

A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.

Publication ,  Conference
Riedel, RF; Ballman, KV; Lu, Y; Attia, S; Loggers, ET; Ganjoo, KN; Livingston, MB; Chow, WA; Wright, JA; Ward, JH; Rushing, DA; Okuno, SH ...
Published in: Journal of Clinical Oncology
May 20, 2018

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2018

Volume

36

Issue

15_suppl

Start / End Page

11505 / 11505

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Riedel, R. F., Ballman, K. V., Lu, Y., Attia, S., Loggers, E. T., Ganjoo, K. N., … Maki, R. G. (2018). A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study. In Journal of Clinical Oncology (Vol. 36, pp. 11505–11505). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.11505
Riedel, Richard F., Karla V. Ballman, Yao Lu, Steven Attia, Elizabeth Trice Loggers, Kristen N. Ganjoo, Michael B. Livingston, et al. “A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.” In Journal of Clinical Oncology, 36:11505–11505. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.11505.
Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, et al. A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 11505–11505.
Riedel, Richard F., et al. “A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 11505–11505. Crossref, doi:10.1200/jco.2018.36.15_suppl.11505.
Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow WA, Wright JA, Ward JH, Rushing DA, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan CW, Reinke DK, Maki RG. A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 11505–11505.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2018

Volume

36

Issue

15_suppl

Start / End Page

11505 / 11505

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences